Incyte Co. (INCY) EVP Reid M. Huber Sells 1,958 Shares

Incyte Co. (NASDAQ:INCY) EVP Reid M. Huber sold 1,958 shares of Incyte stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $85.55, for a total value of $167,506.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Incyte Co. (INCY) traded up $0.48 during trading hours on Thursday, hitting $85.19. The stock had a trading volume of 1,313,626 shares, compared to its average volume of 1,910,000. Incyte Co. has a fifty-two week low of $80.85 and a fifty-two week high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.01 and a quick ratio of 3.99. The company has a market cap of $17,980.00, a PE ratio of -54.61 and a beta of 0.59.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.54. The business had revenue of $444.20 million for the quarter, compared to analysts’ expectations of $435.23 million. Incyte had a negative return on equity of 11.85% and a negative net margin of 20.38%. Incyte’s revenue for the quarter was up 36.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.05 EPS. equities analysts anticipate that Incyte Co. will post -0.18 earnings per share for the current year.

Several equities analysts have recently issued reports on the company. Oppenheimer set a $110.00 target price on Incyte and gave the stock a “hold” rating in a research report on Tuesday. Nomura restated a “buy” rating on shares of Incyte in a research report on Thursday, February 1st. Raymond James Financial restated a “buy” rating on shares of Incyte in a research report on Thursday, February 15th. BidaskClub lowered Incyte from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 1st. Finally, Credit Suisse Group set a $145.00 target price on Incyte and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Incyte has a consensus rating of “Buy” and an average price target of $142.94.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Xact Kapitalforvaltning AB lifted its stake in Incyte by 9.9% in the 4th quarter. Xact Kapitalforvaltning AB now owns 30,627 shares of the biopharmaceutical company’s stock valued at $2,901,000 after acquiring an additional 2,749 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in Incyte by 13.3% in the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 79,710 shares of the biopharmaceutical company’s stock valued at $7,549,000 after acquiring an additional 9,371 shares in the last quarter. Griffin Asset Management Inc. bought a new stake in Incyte in the 4th quarter valued at approximately $200,000. OLD Mutual Customised Solutions Proprietary Ltd. lifted its stake in Incyte by 1,923.9% in the 4th quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 38,292 shares of the biopharmaceutical company’s stock valued at $1,256,000 after acquiring an additional 36,400 shares in the last quarter. Finally, Westover Capital Advisors LLC bought a new stake in Incyte in the 4th quarter valued at approximately $228,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2018/02/22/incyte-co-incy-evp-reid-m-huber-sells-1958-shares.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply